Prospects for personalized rehabilitative medicine
https://doi.org/10.36604/1998-5029-2021-79-117-126
Abstract
A personalized approach, taking into account the genotype and individual characteristics of the patient, provides great opportunities for more effective prevention, treatment and rehabilitation. The review is focused on the main directions of personalized medicine. Prospects for the development of personalized rehabilitative medicine, including the use of non-drug methods, are described. Studies showing the influence of physical factors on the genome are discussed. It has been shown that the effects of physiotherapeutic factors are genetically determined. Advances in the field of physiogenetics indicate the need for developing and implementing personalized rehabilitative technologies.
Keywords
personalized rehabilitative medicine,
physical factors,
genome,
prevention,
treatment,
rehabilitation
Supporting agencies: This study was not sponsored
About the Authors
M. V. Antonyuk
Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitative Treatment;
Pacific State Medical University
Russian Federation
Russian Federation
Marina V. Antonyuk, MD, PhD, DSc (Med.), Рrofessor, Head of Laboratory of Rehabilitative Treatment; Professor of Institute of Clinical Neurology and Rehabilitation Medicine
73g Russkaya Str., Vladivostok, 690105;
4 Ostryakova Ave., Vladivostok, 690002
N. S. Yubitskaya
Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitative Treatment
Russian Federation
Russian Federation
Natalia S. Yubitskaya, MD, PhD (Med.), Staff Scientist of Laboratory of Rehabilitative Treatment
73g Russkaya Str., Vladivostok, 690105
T. A. Gvozdenko
Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitative Treatment;
Pacific State Medical University
Russian Federation
Russian Federation
Tatʹyana A. Gvozdenko, MD, PhD, DSc (Med.), Professor of RAS, Main Staff Scientist of Laboratory of Rehabilitative Treatment, Director; Professor of Institute of Clinical Neurology and Rehabilitation Medicine
73g Russkaya Str., Vladivostok, 690105;
4 Ostryakova Ave., Vladivostok, 690002
S. V. Lebedev
Pacific State Medical University
Russian Federation
Russian Federation
Sergey V. Lebedev, MD, PhD (Med.), Director of the Institute of Clinical Neurology and Rehabilitation Medicine;
4 Ostryakova Ave., Vladivostok, 690002
References
1. Decree of the President of the Russian Federation dated 06.06.2019 No.254 "On the Strategy for the Development of Healthcare in the Russian Federation for the Period until 2025" (in Russian). Available at: https://clck.ru/SKi9e
2. Decree of the President of the Russian Federation dated 01.12.2016 No.642 "On the Strategy of Scientific and Technological Development of the Russian Federation" (in Russian). Available at:https://clck.ru/SKiCV
3. Brunette C.A., Miller S.J., Majahalme N., Hau C., MacMullen L., Advani S., Ludin S.A., Zimolzak A.J., Vassy J.L. Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study. Clin. Transl. Sci. 2020; 13(2):381–390. https://doi.org/10.1111/cts.12723
4. Raskina K.V., Martynova E.Ju., Perfilyev A.V., Sychev D.A., Shuev G.N., Fathutdinov I.R., Musienko S.V., Nikogosov D.A., Zhegulina I.O., Bavykina L.G., Poteshkin Y.E. From personalized to precision medicine. Rational Pharmacotherapy in Cardiology 2017; 13(1):69–79 (in Russian). https://doi.org/10.20996/1819-6446-2017-13-1-69-79
5. Burdennyy A.M., Lukina S.S., Zavarykina T.M., Pronina I.V., Brenner P.K., Kapralova M.A., Atkarskaya M.V., Filippova E.A., Ivanova N.A., Kruglova M.P., Belova M.V., Bahrushina E.O., Braga E.A., Loginov V.I. Pharmacogenetics of drugs in breast cancer and new approaches for improvement of their bioavailability. Patologicheskaya Fiziologiya i Eksperimental'naya Terapiya = Pathological Physiology and Experimental Therapy 2019; 63(4):137–150. (in Russian). https://doi.org/10.25557/0031-2991.2019.04.137-150
6. Bobrova O.P., Dyhno Y.A., Shnayder N.A., Petrova M.M., Zyryanov S.K. Pharmacokinetic and pharmacogenetic aspects of personalized analgetic therapy with fentanil TTS in clinical oncology. Siberian journal of oncology 2018;17(3):94–100. (in Russian). https://doi.org/10.21294/1814-4861-2018-17-3-94-1000
7. Krebs K., Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Human Genomics 2019; 13:39. https://doi.org/10.1186/s40246-019-022
8. Relling M.V, Evans W.E. Pharmacogenomics in the clinic. Nature 2015; 526(7573):343–350. doi: 10.1038/nature15817
9. Gorbat T.V., Nechesova T.A., Liventseva M.M., Korobko I.Yu. Arterial hypertension and hypomagnesemia: pathogenetic possibilities of effective blood pressure control. Lechebnoe delo 2015; (1):7–10 (in Russian).
10. Nasyrova R.F., Sivakova N.A., Ivashchenko D.V., Sosin D.N., Ershov E.E., Sosina K.A., Akhmetova L.S., Volikova O.V., Beybalayeva T.Z., Neznanov N.G. Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-theart. V.M. Bekhterev Review of Psychiatry and Medical Psychology 2016; (3):67–80. (in Russian).
11. Khokhlov L.K., Lukyanov N.E. Pharmacogenetics of antidepressants: from genetic findings to predictive strategies. Acta Biomedica Scientifica (East Siberian Biomedical Journal) 2019; 4(2):33–43 (in Russian) https://doi.org/10.29413/ABS.2019-4.2.5
12. Davis M.E. Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 2016; 20 (5 Suppl.):S2–8. doi: 10.1188/16.CJON.S1.2-8
13. Weinshilboum R.M., Wang L. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin. Proc. 2017; 92(11):1711–1722. doi: 10.1016/j.mayocp.2017.09.001
14. Zhou Y., Ingelman-Sundberg M., Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther. 2017; 102(4):688–700. doi: 10.1002/cpt.690
15. Xie Q., Xiang Q., Mu G., Ma L., Chen S, Zhou S., Hu K, Zhang Z, Cui Y., Jiang J. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. Curr. Pharm. Des. 2018; 24(30):3558–3565. doi: 10.2174/1381612824666181018153641
16. Balabolkin I.I., Bulgakova V.A., Pinelis V.G., Tyumentseva E.S. Pharmacogenetics and individualized approach to the therapy of bronchial asthma. Bulletin of Siberian Medicine 2017; 16(2):20–31 (in Russian). https://doi.org/10.20538/1682-0363-2017-2-20-31
17. Kropacheva E.S. Pharmacogenetics of antithrombotic drugs: status update on the problem. Aterotromboz = Atherothrombosis 2018; (2):115–129 (in Russian). https://doi.org/10.21518/2307-1109-2018-2-115-129
18. Leonova M.V. New data on pharmacogenetics in development of arterial hypertension and effectiveness of amlodipine. Farmakogenetika i farmakogenomika 2018; (1):4–8. (in Russian). https://doi.org/10.24411/2588-0527-2018-10001
19. Raymond J., Imbert L., Cousin T., Duflot T., Varin, R., Wils J., Lamoureux F. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J. Pers. Med. 2021; 11(1):37. https://doi.org/10.3390/jpm11010037
20. van der Wouden C.H., Cambon-Thomsen A., Cecchin E., Cheung K.C., Dávila-Fajardo C.L., Deneer V.H., Dolžan V., Ingelman-Sundberg M., Jönsson S., Karlsson M. O, Kriek M., Mitropoulou C., Patrinos G.P., Pirmohamed M., Samwald M., Schaeffeler E., Schwab M., Steinberger D., Stingl J., Sunder-Plassmann G., Toffoli G., Turner R. M., van Rhenen M. H., Swen J.J., Guchelaar H-J. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin. Pharmacol. Ther. 2017; 101(3):341–58. doi: 10.1002/cpt.602
21. Bogush N.V. Personalized medicine in Russia: current state and main directions of development. In: Innovations in the health of the nation: Proceedings of the VI All-Russian Scientific and Practical Conference. St. Petersburg State Chemical Pharmaceutical University; 2018: 41–45 (in Russian).
22. Dokukina T.V., Gilep A.A., Golubeva T.S., Makhrov M.V., Haidukevich I.V. The development of pharmacogenetic testing to personalize therapy – global health development doctrine. Meditsinskie novosti 2017; (5):45–49 (in Russian).
23. Belushkina N.N., Chemezov A.S., Paltsev M.A. Genetic studies of multifactorial diseases in the concept of personalized medicine. The Russian Journal of Preventive Medicine 2019; 22(3):26–30 (in Russian). https://doi.org/10.17116/profmed20192203126
24. Dedov I.I. Personalized Medicine. Annals of the Russian academy of medical sciences 2019; 74(1):61–70. doi: 10.15690/vramn1108
25. Personalized Medicine Coalition (PMC). Available at: http://www.personalizedmedicinecoalition.org
26. Patrinos G.P., Mitropoulou C. Measuring the value of pharmacogenomics evidence. Clin. Pharmacol. Ther. 2017; 102(5):739–741. https://doi.org/10.1002/cpt.743
27. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat. Med. 2012; 18(3):326. https://doi.org/10.1038/nm0312-326
28. Volpi S., Bult C.J., Chisholm R.L., Deverka P.A., Ginsburg G.S., Jacob H.J., Kasapi M., McLeod H.L., Roden D.M., Williams M.S., Green E.D., Rodriguez L.L., Aronson S., Cavallari L.H., Denny J.C., Dressler L.G., Johnson J.A., Klein T. E., Leeder J. S., Piquette-Miller M., Perera M., Rasmussen-Torvik L.J., Rehm H.L., Ritchie M.D., Skaar T.C., Wagle N. , Weinshilboum R., Weitzel K.W., Wildin R., Wilson J., Manolio T.A., Relling M.V. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin. Pharmacol Ther. 2018; 103(5):778–786. https://doi.org/10.1002/cpt.1048
29. Hoggatt J. Personalized medicine – trends in molecular diagnostics: exponential growth expected in the next ten years. Mol. Diagn. Ther. 2011; 15(1):53–55. https://doi.org/10.2165/11534880-000000000- 00000
30. Chiari-Andréo B.G., Abuçafy M.P., Manaia E.B., da Silva B.L., Rissi N.C., Oshiro-Júnior J.A., Chiavacci L.A. Drug Delivery Using Theranostics: An Overview of its Use, Advantages and Safety Assessment. Current Nanoscience 2020; 16(1):3–14. https://doi.org/10.2174/1573413715666190618162321
31. Hodgson D.R., Wellings R., Harbron C. Practical perspectives of personalized health care in oncology. N. Biotechnol. 2012; 29(6):656–664. https://doi.org/10.1016/j.nbt.2012.03.001
32. Letai A. Functional precision cancer medicine—moving beyond pure genomics. Nat. Med. 2017; 23(9):1028–1035. https://doi.org/10.1038/nm.4389
33. Wu J., Izpisua Belmonte J.C. Stem cells: a renaissance in human biology research. Cell 2016; 165(7): 1572–1585. https://doi.org/ 10.1016/j.cell.2016.05.043
34. Ponomarenko G.N., Ulashhik B.C. Physiotherapy: Molecular Basics. St. Petersburg; 2014 (in Russian).
35. Antonyuk M.V., Gvozdenko T.A., Yubitskaya N.S., Shatilov I.N. Sanatorium-resort treatment of patients with chronic cholecystitis in combination with metabolic syndrome. Kurortnaya meditsina 2016; (3):40–45 (in Russian).
36. Tsareva U.V., Demeev Ya.A., Skachkov O.A., Sheverdina E.A. Treatment of patients with bronchial asthma associated with obesity in a health resort "Okeanskiy". Voenno-meditsinskiy zhurnal 2015; 336(6):25–29 (in Russian).
37. Ponomarenko G.N. Topical issues of physiotherapy: Selected lectures. St. Peterburg; 2010 (in Russian).
38. Krysyuk O.B., Obrezan A.G., Ponomarenko G.N. Problems of personalized medicine in the clinic of internal diseases. Vestnik Sankt-Peterburgskogo universiteta 2006; (1):16–22 (in Russian).
39. Steube A., Schenk T., Tretyakov A., Saluz H. High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells. Nat. Commun. 2017; 8(1):1303. https://doi.org/10.1038/s41467-017-01251-7
40. Brill G.E., Bugaeva I.O. Changes of deproteidized DNA and RNA levels in the cells of lymphatic tissues after infra-red laser irradiation of animals. Lazernaya meditsina 2005; 9(3):48–52 (in Russian).
41. Brill G.E., Egorova A.V., Bugaeva I.O., Ushakova O.V., Matyushkina O.L. Different reaction of core histones H2a and H2b to the red laser radiation. Saratov Journal of Medical Scientific Research 2017; 13(3):469–472 (in Russian).
42. Brill G.E., Egorova A.V., Dubovitskiy V.A., Vlaskin S.V. Histones – possible triggers of the influence of electromagnetic radiation on the cellular genome. In: Proceedings of the XXXVII International Scientific and Practical Conference "Application of lasers in medicine and biology". Yalta; 2012: 97–98 (in Russian).
43. Brill G.E., Egorova A.V., Bugaeva I.O., Postnov D.E. Red laser light effects at the structure formaiton of core histones. Lazernaya meditsina 2013; 17(3):23–27 (in Russian).
44. Müller S., Fritz Y., Wagenknecht H.A. Control of Energy Transfer Between Pyrene- and Perylene-Nucleosides by the Sequence of DNA-Templated Supramolecular Assemblies. Chemistry Open 2020; 9(4):389–392. https://doi.org/10.1002/open.201900346
45. Khairutdinov V.R., Pilyugin N.V., Ponomarenko G.N., Samtsov A.V., Imyanitov E.N. Genetic determinants of the efficiency of medium-wavelength ultraviolet irradiation of patients presenting with psoriasis. Voprosy kurortologii i lechebnoy fizicheskoy kul'tury 2010; (6):3–5 (in Russian).
46. Kovlen D.V., Tishakova A.Yu., Glotov O.S., Moskalenko M.V., Demin G.S., Bitsadze A.N., Chernyshev A.V., Bratova N.M., Ivashhenko T.E., Obrezan A. G., Ponomarenko G.N. Genetic determinants of the effectiveness of climatotherapy in patients with chronic heart failure. Bull. Exp. Biol. Med. 2007; 143(1):26–31 (in Russian). doi: 10.1007/s10517-007-0008-z
47. Lee T.H., Kang T.H. DNA Oxidation and Excision Repair Pathways. Int. J. Mol. Sci. 2019; 20(2):6092. https://doi.org/10.3390/ijms20236092
48. Kytikova O.Yu., Gvozdenko T.A. On the issue of genetic toxicity of biooxidative therapy. In: Proceedings of the International Scientific and Practical Conference "Education and Science: Current State and Development Prospects". Tambov; 2015: 3:37–39 (in Russian). ISBN: 978-5-9907209-6-1
49. Kytikova O.Yu., Gvozdenko T.A., Vitkina T.I., Novgorodtsev A.D. Genotoxic effect of oxidative stress in elderly patients with chronic obstructive pulmonary disease. Bûlleten' fiziologii i patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2015; 56:46–49 (in Russian).
50. Kytikova O.Yu., Gvozdenko T.A., Novgorodtsev A.D. Pathophysiological targets of ozonetherapy in gerontology and geriatrics. Vladivostok: Dal'nauka; 2016 (in Russian).
51. Kytikova O.Yu., Gvozdenko T.A. The level of oxidative damage to DNA as a safety marker of ozonetherapy. In: Theoretical and applied aspects of modern science: Materials of the VIII International Scientific-Practical Conference. 2015; (8-1):118–120 (in Russian).
52. Gvozdenko T.A., Antonyuk M.V., Vitkina T.I., Kytikova O.Yu., Yurenko A.V. Differentiated application of ozone therapy in the rehabilitation treatment of patients with chronic obstructive pulmonary disease: Medical technology. Vladivostok; 2016 (in Russian).
Review
For citations:
Antonyuk M.V., Yubitskaya N.S., Gvozdenko T.A., Lebedev S.V. Prospects for personalized rehabilitative medicine. Bulletin Physiology and Pathology of Respiration. 2021;(79):117-126. (In Russ.) https://doi.org/10.36604/1998-5029-2021-79-117-126
Views:
354
Email this article 